Presentation is loading. Please wait.

Presentation is loading. Please wait.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Published byHadi Kurniawan Modified over 6 years ago

Similar presentations

Presentation on theme: "Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall."— Presentation transcript:

1 Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall survival. Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall survival. AA, abiraterone acetate; PSA, prostate-specific antigen. Ana Fröbe et al. ESMO Open 2016;1:e000049 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall."

Similar presentations

Volume 27, Issue 4, Pages (December 2016)

Volume 27, Issue 4, Pages (December 2016)
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.

Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Overview of the QTWiST method

Overview of the QTWiST method
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram

PRISMA study flow diagram
Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.
Methods distribution among the three EQAs

Methods distribution among the three EQAs
Plot with best overall response and study duration.

Plot with best overall response and study duration.
Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.
Comparison of the LL95%CI rule with PE rules with similar behaviour: %acceptance of maximal RB for power 80% and 90% over all trials, for LL95%CI ≤0.65 rule,

Comparison of the LL95%CI rule with PE rules with similar behaviour: %acceptance of maximal RB for power 80% and 90% over all trials, for LL95%CI ≤0.65 rule,

Similar presentations

Ads by Google